Aluda was founded around the idea that we need new approaches to drug discovery to find fundamentally new categories and identify better, more powerful intervention points against disease. We bring a deep, networked view of existing drug MOAs and screening approaches of the past 30 years, from signalling pathways to genetics and non-traditional targets. Our focus is on novel targets that have been under-explored for their impact on cellular process.

Disease is always complex — it is never one cause, one event — and the relationship between its many features is not always linear or related. We seek to find a new generation of targets with broader roles that block more of disease for a leap forward for patients.